8-K: Catheter Precision Enters Into $1.3 Million At-The-Market Offering Agreement with Ladenburg Thalmann

Catheter Precision, Inc. has entered into an agreement with Ladenburg Thalmann & Co. Inc. to offer and sell up to $1.3 million of its common stock through an at-the-market offering.

Summary

• Catheter Precision, Inc. has entered into an At Market Offering Agreement with Ladenburg Thalmann & Co. Inc. on May 19, 2025.
• The company may offer and sell up to $1.3 million of its common stock (the Shares) from time to time through Ladenburg.
• The Shares will be issued under a previously filed and effective Registration Statement on Form S-3.
• The company intends to use the net proceeds from the offering to fund its operations and for working capital.
• The company is not obligated to sell any shares under the agreement.
• Ladenburg will use commercially reasonable efforts to sell shares based on the company's instructions, including any price, time, or size limits.
• Ladenburg may sell shares through various methods, including directly on the NYSE American, other trading markets, or to market makers.
• The agreement may be terminated by either party with five business days' notice or by Ladenburg under certain circumstances, such as a material adverse effect on the company.
• The company will pay Ladenburg a commission equal to 3.0% of the gross proceeds from each sale of shares.
• The agreement includes customary indemnification and contribution rights for Ladenburg.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, which can be seen as a positive, it also indicates a need for funds and potential dilution for existing shareholders. The terms of the agreement are standard for this type of offering.

Positives

• The At Market Offering Agreement provides Catheter Precision with a flexible way to raise capital.
• The company retains control over the timing and amount of shares sold.
• The proceeds from the offering will be used to fund operations and working capital.

Negatives

• The company will incur a 3.0% commission on the gross proceeds from each sale, reducing the net amount received.
• There is no guarantee that the company will be able to sell all of the shares offered.
• The offering could potentially dilute existing shareholders' equity.

Risks

• The company's stock price could be negatively impacted by the offering.
• The company may not be able to achieve its desired funding level if market conditions are unfavorable.
• A material adverse effect on the company could lead to termination of the agreement by Ladenburg.

Future Outlook

The company intends to use the net proceeds from the offering, if any, to fund its operations and for working capital.

Industry Context

At-the-market offerings are a common method for small-cap companies to raise capital gradually without the need for a traditional underwritten offering. This approach allows companies to take advantage of market conditions and minimize the impact on their stock price.

Comparison to Industry Standards

• Comparable companies in the medical device sector, such as BIOLASE, Inc. and PAVmed Inc., have also utilized at-the-market offerings to raise capital.
• The commission rate of 3.0% is within the typical range for ATM offerings, which can vary based on the size of the offering and the underwriter's role.
• The intended use of proceeds for general operations and working capital is standard for companies in this stage of development.

Stakeholder Impact

• Shareholders may experience dilution of their ownership if the company sells all of the shares offered.
• The company's employees and customers may benefit from the additional funding for operations and working capital.
• The company's creditors may be impacted by the additional capital, which could improve the company's financial stability.

Next Steps

• The company will file a prospectus supplement related to the offer and sale of the Shares.
• Ladenburg will use commercially reasonable efforts to sell the shares from time to time based on the company's instructions.
• The company will disclose the number of shares sold, net proceeds, and compensation paid in its future SEC filings.

Key Dates

Keywords

At Market Offering, Common Stock, Ladenburg Thalmann, Capital Raise, Catheter Precision, Securities Offering, VTAK